Organon & Co. (NYSE:OGN) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Organon & Co. has received an average rating of "Moderate Buy" from six analyst firms, with a 1-year price target of $17.33.
• The company reported a quarterly earnings beat, with $1.00 earnings per share, surpassing analysts' expectations of $0.94.
• Organon also announced a quarterly dividend of $0.02, yielding 0.7%, with its dividend payout ratio currently at 2.97%.

Organon & Co. (NYSE:OGN - Get Free Report) has received an average recommendation of "Moderate Buy" from the six ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $17.3333.

Separately, Weiss Ratings restated a "sell (d+)" rating on shares of Organon & Co. in a research note on Saturday, September 27th.

Institutional Trading of Organon & Co.

A number of large investors have recently bought and sold shares of the business. Massachusetts Financial Services Co. MA lifted its position in shares of Organon & Co. by 8.3% in the first quarter. Massachusetts Financial Services Co. MA now owns 10,715,445 shares of the company's stock valued at $159,553,000 after acquiring an additional 820,378 shares in the last quarter. State Street Corp raised its stake in shares of Organon & Co. by 6.0% in the 2nd quarter. State Street Corp now owns 9,520,594 shares of the company's stock worth $92,159,000 after buying an additional 540,478 shares in the last quarter. LSV Asset Management raised its position in Organon & Co. by 6.1% during the first quarter. LSV Asset Management now owns 7,980,775 shares of the company's stock valued at $118,834,000 after buying an additional 455,699 shares during the period. Nordea Investment Management AB boosted its stake in shares of Organon & Co. by 1.1% during the 2nd quarter. Nordea Investment Management AB now owns 4,904,076 shares of the company's stock worth $48,281,000 after acquiring an additional 53,733 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in Organon & Co. by 136.1% during the 2nd quarter. AQR Capital Management LLC now owns 3,254,884 shares of the company's stock valued at $31,507,000 after purchasing an additional 1,876,264 shares during the period. Institutional investors and hedge funds own 77.43% of the company's stock.

Organon & Co. Stock Performance

NYSE:OGN traded up $0.09 during trading on Friday, reaching $11.03. The company's stock had a trading volume of 4,256,142 shares, compared to its average volume of 3,715,210. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of 4.10, a price-to-earnings-growth ratio of 1.00 and a beta of 0.63. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $19.05. The firm has a 50 day moving average of $9.86 and a 200-day moving average of $10.41.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.06. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The firm had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.55 billion. During the same quarter last year, the firm posted $1.12 EPS. The company's revenue was down .8% compared to the same quarter last year. Organon & Co. has set its FY 2025 guidance at EPS. Research analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Investors of record on Friday, August 15th were given a $0.02 dividend. The ex-dividend date was Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a yield of 0.7%. Organon & Co.'s dividend payout ratio is currently 2.97%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.